Ataxia

Hi Everyone, Susan is inviting our SCA6 Network group to join her AR&DG Zoom group for yoga on Monday with Shannon Reeder, a certified yoga instructor. If you are interested, please see Susan's message below. Topic: Yoga Therapy by Shannon Reedy Time:  Sep 29, 2025 03:00 PM Eastern Time  (US and Canada) Join Zoom Meeting https://us02web.zoom.us/j/2276674020?pwd=2Q5SNLyrcGDw9hp0Xt6xkvsonFeNo8.1&omn=81312156639 View meeting insights with Zoom AI Companion https://us02web.zoom.us/launch/edl?muid=08b86098-b164-41a9-b1a7-80c96fda5e76 Meeting ID: 227 667 4020 Passcode: ataxia --- One tap mobile +13017158592,,2276674020#,,,,*950030#  US ( Washington DC ) +13052241968,,2276674020#,,,,*950030#  US Join instructions https://us02web.zoom.us/meetings/81312156639/invitations?signature=amoH3Df3hmmicLFHHJtpAmlwG_MuhjsGiEDoTzeJ2kY Hi all: This  coming Monday , we will be having Shannon Reeder, a registered yoga teacher, give us an introduction of yoga therapy and s...

uniQure  N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced positive topline data from the pivotal Phase I/II study of AMT-130 for the treatment of Huntington’s disease. The study met its prespecified primary endpoint, with high-dose AMT-130 demonstrating a statistically significant slowing of disease progression as measured by the composite Unified Huntington’s Disease Rating Scale (cUHDRS) at 36 months compared to a propensity score-matched external control. The study also met a key secondary endpoint by achieving statistically significant slowing of disease progression as measured by Total Functional Capacity (TFC) at 36 months compared to a propensity score-matched external control. https://uniqure.gcs-web.com/news-releases/news-release-details/uniqure-announces-positive-topline-results-pivotal-phase-iii Although this is not for SCA6, successful one-time administration of gene therapy (a...